EUVIMEDEUVIMED entdecken
Fallbericht

Hyperacute Progression of Sinonasal NUT Carcinoma After Pembrolizumab‐Based Treatment: A Case Report

Zhuomiao Ye iD, Dan Yang, Fei Xie, Minghui Zhang, Cailiang Gao, Yunjin Xie, Xin Li, Mingzhu Yin

The Laryngoscope · 2026-12 · 136 (12) · 5312-5315

DOI: 10.1002/lary.70733 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Laryngoscope, online erschienen am 08.07.2026. Verfasst von Zhuomiao Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Paranasal Sinus Neoplasms. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Science and Technology Innovation Key R&D Program of Chongqing, the Natural Science Foundation of Chongqing (Innovation and Development Joint Fund Project, The Natural Science Foundationof Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This case report describes hyperacute destructive progression of sinonasal NUT carcinoma with new osseous metastasis shortly after pembrolizumab-based immunochemotherapy. The clinical course highlights the importance of early NUT testing, proactive systemic surveillance, cautious interpretation of immunotherapy response, and timely consideration of BET inhibition or clinical trial referral.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinomaParanasal Sinus NeoplasmsMaxillary Sinus NeoplasmsHumansDisease ProgressionNuclear ProteinsMaleNeoplasm Proteins

Stichwörter der Autor:innen

BET inhibitorNUT carcinomaNUTM1 rearrangementhyperacute progressionimmunotherapysinonasal malignancy

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, ImmunologicalNUTM1 protein, humanNuclear ProteinsNeoplasm Proteins

Autor:innen und Institutionen

  • Clinical Research Center (CRC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
  • Cancer Early Detection and Treatment Center (CEDTC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
  • Department of Breast Surgery, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
  • Department of Nuclear Medicine, Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
  • Medical Pathology Center (MPC), Chongqing University Three Gorges Hospital, Chongqing University, Chongqing, China.
  • Chongqing University Three Gorges Hospital & Academy for Advanced Interdisciplinary Technology, CQU - Ferenc Krausz Nobel Laureate Scientific, Chongqing, China.

ORCID-Profile: Zhuomiao Ye

Förderung

  • Science and Technology Innovation Key R&D Program of Chongqing
  • the Natural Science Foundation of Chongqing (Innovation and Development Joint Fund Project
  • The Natural Science Foundationof Chongqing

Zitieren

APA

Ye, Z., Yang, D., Xie, F., Zhang, M., Gao, C., Xie, Y., Li, X., & Yin, M. (2026). Hyperacute Progression of Sinonasal NUT Carcinoma After Pembrolizumab‐Based Treatment: A Case Report. The Laryngoscope, 136(12), 5312-5315. https://doi.org/10.1002/lary.70733

Vancouver

Ye Z, Yang D, Xie F, Zhang M, Gao C, Xie Y, et al. Hyperacute Progression of Sinonasal NUT Carcinoma After Pembrolizumab‐Based Treatment: A Case Report. The Laryngoscope. 2026;136(12):5312-5315. doi:10.1002/lary.70733

BibTeX
@article{Ye2026,
  author = {Ye, Zhuomiao and Yang, Dan and Xie, Fei and Zhang, Minghui and Gao, Cailiang and Xie, Yunjin and Li, Xin and Yin, Mingzhu},
  title = {Hyperacute Progression of Sinonasal NUT Carcinoma After Pembrolizumab‐Based Treatment: A Case Report},
  journal = {The Laryngoscope},
  year = {2026},
  volume = {136},
  number = {12},
  pages = {5312--5315},
  doi = {10.1002/lary.70733}
}
Kostenlos starten →